



AIM: RENE

5 May 2017

ReNeuron Group plc

ReNeuron presents new data with its exosome therapy programme at major scientific conference

ReNeuron Group plc (the "Company") (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce that it will today be presenting new data relating to the characterisation and scale-up of its CTX cell-derived exosome therapy candidates at a leading scientific conference in London.

In a poster presentation, ReNeuron researchers and their academic collaborators at the Department of Biochemical Engineering, University College London, address the challenges of purifying CTX-derived exosomes at scale whilst preserving their potential therapeutic attributes to ensure consistency of future manufacture. New strategies are presented to address the upstream cell culture processes needed to generate the exosomes and the downstream purification methods that can be applied to remove protein and DNA-based impurities from the exosomes at commercially relevant scale. These new methods yielded a three-fold increase in particle protein purity and a more than five-fold increase in particle DNA purity compared with previous purification processes.

In a further poster presentation, research teams at ReNeuron and at the UK's Cell and Gene Therapy Catapult address the challenge of characterising ReNeuron's CTX cell-derived exosomes to ensure consistency and control during manufacture. The studies undertaken demonstrated a robust approach to optimising and qualifying assays for micro-RNA ("miRNA") targets found in the exosomes. A potential advantage of exosomes when utilised as a carrier for the delivery of therapeutic miRNAs in gene therapy is the avoidance of issues typically encountered by RNA-based drugs such as stability *in vivo* and tissue targeting.

The application of robust characterisation and purification methods to ReNeuron's exosome populations will support future development of the Company's exosome-based therapeutic candidates across multiple potential disease indications, the initial disease target being cancer.

The above data are being presented today at the International Society for Cellular Therapy (ISCT) 2017 Annual Meeting in London. ReNeuron's Chief Executive Officer, Olav Hellebø, will also be speaking on "Commercialisation requirements

for cell and gene therapies” in a plenary session at the conference. Further information about this conference may be found at www.isct2017.com.

Dr Randolph Corteling, Head of Research at ReNeuron, said:

“The data being presented at the ISCT 2017 conference represent key advances in the development of ReNeuron’s CTX-derived exosome therapeutic programme, both as a potential new nanomedicine targeting cancer and as a potential delivery system for gene therapy treatments. We look forward to presenting further data from this programme in the months ahead.”

ENDS

ENQUIRIES:

ReNeuron +44 (0)20 3819 8400

Olav Hellebø , Chief Executive Officer

Michael Hunt, Chief Financial Officer

Buchanan +44 (0) 20 7466 5000

Mark Court, Sophie Cowles, Stephanie Watson

Stifel Nicolaus Europe Limited +44 (0) 20 7710 7600

Jonathan Senior, Stewart Wallace, Ben Maddison (NOMAD and Broker)

About ReNeuron

ReNeuron is a leading, clinical-stage cell therapy development company. Based in the UK, its primary objective is the development of novel cell-based therapies targeting areas of significant unmet or poorly met medical need.

ReNeuron has used its unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered “off-the-shelf” to any eligible patient without the need for additional immunosuppressive drug treatments. The Company has therapeutic candidates in clinical development for motor disability as a result of stroke, for critical limb ischaemia and for the blindness-causing disease, retinitis pigmentosa.

ReNeuron is also advancing its proprietary exosome technology platform as a potential new nanomedicine targeting cancer and as a potential delivery system for gene therapy treatments.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. Further information on ReNeuron and its products can be found at www.reneuron.com.

This announcement contains forward-looking statements with respect to the financial condition, results of operations and business achievements/performance of ReNeuron and certain of the plans and objectives of management of ReNeuron with respect thereto. These statements may generally, but not always, be identified by the use of words such as "should", "expects", "estimates", "believes" or similar expressions. This announcement also contains forward-looking statements attributed to certain third parties relating to their estimates regarding the growth of markets and demand for products. By their nature, forward-looking statements involve risk and uncertainty because they reflect ReNeuron's current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of factors could cause ReNeuron's actual financial condition, results of operations and business achievements/performance to differ materially from the estimates made or implied in such forward-looking statements and, accordingly, reliance should not be placed on such statements.